Healthy Volunteers
Conditions
Brief summary
This is an open-labeled, cross-over design, pharmacokinetic study, to determine the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in healthy volunteers, aged 55-75, and in good general health.
Detailed description
This is an open-labeled, cross-over design, pharmacokinetic study, where 24 subjects will be randomly assigned to receive treatment regimen A-B or B-A on two consecutive days of dosing. Two dosing groups are planned for the study : * Group 1 (n=12) * Group 2 (n=12) Each group will be admitted to the Phase I Unit the evening before dosing and will initiate dosing the next morning for 2-days of consecutive treatment (A-B, or B-A). Both groups will undergo identical study related procedures, except those subjects that consent to CSF collection on Day 1 of dosing. Dose regimen A consists of a single inhaled oral dose of ALZT-OP1a via dry powder inhaler + a single oral tablet dose of ALZT-OP1b. Dose regimen B consists of two oral inhaled doses of ALZT-OP1a, not more than 2 minutes apart, via dry powder inhaler + two oral tablet doses of ALZT-OP1b. Plasma Collection, All Subjects (n=24) 1 mL blood samples will be collected at T: 0, 5, 10, 15, 30, 1 hr, 2 hr, 4 hr, and 6 hours, following ALZT-OP1 administration (Days 1 and 2). CSF Collection, Sub-group (n=12) A sub-group of 12 subjects will be consented for CSF collection. 1 mL of CSF will be collected at T: 0, 5 min, 30 min, 2 hr, and 4 hours, following ALZT-OP1 administration (Day 1 only).
Interventions
DRUGALZT-OP1a
Mast cell stabilizer
DRUGALZT-OP1b
anti-inflammatory
DEVICEDry Powder Inhaler
The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
Sponsors
Panax Clinical Research
Pharma Consulting Group AB
KCAS
AZTherapies, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Provide a signed written informed consent; * Age 55-75 inclusive; * ECG within normal limits; * Body mass index (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2; * Negative urine drug screen for selected drugs of abuse at screening; * Negative for hepatitis and HIV at screening; * Good general health, as determined by medical history, physical examination, and clinical laboratory testing; * Willingness to stay in the unit overnight for the duration of the study; * Consent for CSF collection (for those in CSF group).
Exclusion criteria
* Current smokers, or ex-smokers with a remote history (\> 100 pack/year); * Clinically significant medical conditions; * History of ECG abnormalities; * Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing; * Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in absence of febrile episodes, in the last 14 days; * History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism, and excretion of drugs; * Malignancy, regardless of location; * Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis; * Investigational agents are prohibited one month prior to entry and for the duration of the trial; * Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin); * Currently taking cromolyn, or have taken cromolyn, within the past 30 days; * NSAID use (products containing ibuprofen while on study); * Aspirin, or products containing aspirin, while on study; * Allergy or hypersensitivity to cromolyn (also known as Intal®, Nasalcrom®, etc.); * Allergy or hypersensitivity to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin, including Stevens-Johnson syndrome; * History of hypersensitivity or allergies to any of the drug compound under investigation (cromolyn, ibuprofen, lactose, or magnesium stearate); * History of clinically significant respiratory disorders and chronic respiratory disease with impaired respiratory effort or difficulty taking inhaled drugs (examples: COPD, emphysema); * Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC \< 70% of the predicted value for the subject, when compared to reference values; AND FEV1 and FVC \< 70% of predicted value when compared to reference values, indicating moderate to severe respiratory obstruction; * Any other disease or condition, which, in the opinion of the investigator, would make the subject unsuitable for this study; * Female subjects of reproductive potential with a positive pregnancy test (urine or serum) or who are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-compartmental plasma pharmacokinetics for ALZT-OP1a and ALZT-OP1b | T=0 to 6 hours (0, 5, 10, 15, 30, 60, 120, 240, and 360 minutes) | * AUC (0-∞) (area under the curve from 0 to infinity) * AUC (0-t) (area under the curve from 0 to t hours where t is the last measured concentration * AUCPLASMA/AUCCSF (ratio at 5 min, 30 min, 2 hr and 4 hours) * CL/F (apparent total body clearance) * Cmax (maximum plasma concentration observed) * T ½ (half life) * Tmax (sampling time at which Cmax occurred) * Vd/F (apparent volume of distribution Plasma concentration-time profiles will be presented for both study drugs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of ALZT-OP1a and ALZT-OP1b in cerebrospinal fluid (CSF) | T=0 to 4 hours (0, 5, 30, 120, and 240 minutes) | CSF samples will be collected at 5 time-points to measure levels of ALZT-OP1a and ALZT-OP1b in CSF. |
| Number of Treatment Emergent Adverse Events (TEAE) | 2 days | Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events. They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment. The AEs will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing was initiated. |
Countries
United States
Outcome results
None listed